Boryung Corporation (formerly Boryung Pharmaceutical Co., Ltd.) is a South Korean life-science and healthcare conglomerate that, acting as the investment arm of its operating parent, deploys corporate venture capital into startups spanning pharmaceuticals, biotech, and space-based healthcare. Since 2022, it has invested $50 million in Axiom Space's Series C round, partnered with Starburst Aerospace to run the Care In Space accelerator program, and created the BRAX Space joint venture.
33% of their portfolio is in Defense & Space. Average disclosed round size is $91.8M (across 4 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Unknown
Last 12 Mo
0
Team
JW
Jinsol Woo
Investment Team, Business Strategic Division
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Exobiosphere | Seed | — | Apr 2025 |
 LambdaVision Incorporated | Unknown | $17M | May 2024 |
 Axiom Space | Series C | $350M | Aug 2023 |
| Axiom Space | Growth | — | Aug 2023 |
| DDeep Space Biology | Unknown | $100K | — |
| VViBo Health | Unknown | $100K | — |
Top Co-Investors
Expon Capital1 shared
Aurelia Foundry1 shared
E2MC1 shared
Connecticut Innovations1 shared
Aljazira Capital1 shared
Type One Ventures1 shared
Hemisphere Ventures1 shared
1789 Capital1 shared
Last updated: 8 November 2026